Dialysis devices maker NxStage Medical calls on the Centers for Medicare & Medicaid Services to update its "insufficient and inequitable" payment rules for home hemodialysis.

NxStage Medical logo

NxStage Medical (NSDQ:NXTM) is still fighting the Centers for Medicare & Medicaid Services on its proposed rule for home hemodialysis treatment.

The dialysis devices maker submitted a public comment on the updated rule, calling for more support for HHD therapy, especially in terms of training.

"The status quo is inconsistent with the Congressional mandate to bring patients home and is a huge factor in Medicare [end stage renal disease] patients' limited access to more frequent HHD," NxStage Medical North America president Joe Turk said in prepared remarks. "This issue can and should be addressed to allow patients better access to this life-changing therapy, that so often leads to longer, healthier lives for patients who require dialysis to live."